Compugen (NASDAQ:CGEN) Stock Crosses Above Two Hundred Day Moving Average of $1.63

Compugen Ltd. (NASDAQ:CGEN) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.63 and traded as high as $2.25. Compugen shares last traded at $2.13, with a volume of 388,383 shares traded.

Analyst Ratings Changes

Several analysts recently commented on the company. Stifel Nicolaus boosted their price target on Compugen from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, December 19th. StockNews.com upgraded Compugen from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th.

Compugen Price Performance

The stock has a 50 day simple moving average of $2.48 and a two-hundred day simple moving average of $1.63. The company has a market cap of $184.51 million, a price-to-earnings ratio of -9.68 and a beta of 2.63.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, March 5th. The biotechnology company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.10 by $0.01. The business had revenue of $33.46 million during the quarter, compared to analyst estimates of $60.00 million. As a group, research analysts forecast that Compugen Ltd. will post 0.02 EPS for the current year.

Hedge Funds Weigh In On Compugen

Several large investors have recently modified their holdings of the business. Envestnet Asset Management Inc. lifted its stake in Compugen by 23.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 33,260 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 6,299 shares in the last quarter. Advisor Group Holdings Inc. increased its holdings in Compugen by 29.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 27,241 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 6,174 shares during the period. Swiss National Bank increased its holdings in Compugen by 9.0% during the 1st quarter. Swiss National Bank now owns 199,600 shares of the biotechnology company’s stock worth $643,000 after purchasing an additional 16,400 shares during the period. JPMorgan Chase & Co. increased its holdings in Compugen by 78.4% during the 1st quarter. JPMorgan Chase & Co. now owns 297,110 shares of the biotechnology company’s stock worth $957,000 after purchasing an additional 130,564 shares during the period. Finally, Panagora Asset Management Inc. purchased a new stake in Compugen during the 1st quarter worth about $152,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.